288 related articles for article (PubMed ID: 12543084)
1. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Akbulut H; Altuntas F; Akbulut KG; Ozturk G; Cindoruk M; Unal E; Icli F
Cytokine; 2002 Nov; 20(4):184-90. PubMed ID: 12543084
[TBL] [Abstract][Full Text] [Related]
2. Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma.
Berglund A; Molin D; Larsson A; Einarsson R; Glimelius B
Ann Oncol; 2002 Sep; 13(9):1430-7. PubMed ID: 12196369
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma.
Werther K; Christensen IJ; Nielsen HJ;
Br J Cancer; 2002 Feb; 86(3):417-23. PubMed ID: 11875709
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery.
Chao Y; Li CP; Chau GY; Chen CP; King KL; Lui WY; Yen SH; Chang FY; Chan WK; Lee SD
Ann Surg Oncol; 2003 May; 10(4):355-62. PubMed ID: 12734082
[TBL] [Abstract][Full Text] [Related]
5. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course.
Osella-Abate S; Quaglino P; Savoia P; Leporati C; Comessatti A; Bernengo MG
Melanoma Res; 2002 Aug; 12(4):325-34. PubMed ID: 12170181
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
Hassan AS; Naicker M; Yusof KH; Wan Ishak WZ
Asian Pac J Cancer Prev; 2015; 16(6):2237-43. PubMed ID: 25824744
[TBL] [Abstract][Full Text] [Related]
7. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients.
Brattström D; Bergqvist M; Hesselius P; Larsson A; Lamberg K; Wernlund J; Brodin O; Wagenius G
Lung Cancer; 2002 Jul; 37(1):57-63. PubMed ID: 12057868
[TBL] [Abstract][Full Text] [Related]
8. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients.
Dirix LY; Vermeulen PB; Pawinski A; Prové A; Benoy I; De Pooter C; Martin M; Van Oosterom AT
Br J Cancer; 1997; 76(2):238-43. PubMed ID: 9231925
[TBL] [Abstract][Full Text] [Related]
9. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
[TBL] [Abstract][Full Text] [Related]
10. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
Cetin B; Kaplan MA; Berk V; Ozturk SC; Benekli M; Isıkdogan A; Ozkan M; Coskun U; Buyukberber S
Asian Pac J Cancer Prev; 2012; 13(3):1059-63. PubMed ID: 22631638
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors associated with primary cancer in curatively resected stage IV colorectal cancer.
Huh JW; Lee WY; Park YA; Cho YB; Yun SH; Kim HC; Chun HK
J Cancer Res Clin Oncol; 2014 Mar; 140(3):435-41. PubMed ID: 24414039
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer.
Landriscina M; Cassano A; Ratto C; Longo R; Ippoliti M; Palazzotti B; Crucitti F; Barone C
Br J Cancer; 1998 Sep; 78(6):765-70. PubMed ID: 9743297
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
Lin L; Xu JM; Wang Y; Ge FJ; Liu LJ; Zhao CH; Li SS; Liu JZ; Li ZQ
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):786-90. PubMed ID: 21163073
[TBL] [Abstract][Full Text] [Related]
15. Predictive Significance of VEGF and HIF-1α Expression in Patients with Metastatic Colorectal Cancer Receiving Chemotherapy Combinations with Bevacizumab.
Berk V; Deniz K; Bozkurt O; Ozaslan E; Karaca H; Inanc M; Duran AO; Ozkan M
Asian Pac J Cancer Prev; 2015; 16(14):6149-54. PubMed ID: 26320510
[TBL] [Abstract][Full Text] [Related]
16. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms.
Choe JH; Overman MJ; Fournier KF; Royal RE; Ohinata A; Rafeeq S; Beaty K; Phillips JK; Wolff RA; Mansfield PF; Eng C
Ann Surg Oncol; 2015 Aug; 22(8):2578-84. PubMed ID: 25582740
[TBL] [Abstract][Full Text] [Related]
17. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
18. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma.
Poon RT; Lau CP; Cheung ST; Yu WC; Fan ST
Cancer Res; 2003 Jun; 63(12):3121-6. PubMed ID: 12810638
[TBL] [Abstract][Full Text] [Related]
19. [Impact of adjuvant chemotherapy duration on 3-year disease-free survival of colorectal carcinoma patients after radical resection].
Qiu MZ; Teng KY; Ruan DY; Li YH; Chen XQ; Pan ZZ; He YJ; Wan DS; Xu RH
Ai Zheng; 2009 Jul; 28(7):743-8. PubMed ID: 19624903
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.
Hayashi H; Arao T; Matsumoto K; Kimura H; Togashi Y; Hirashima Y; Horita Y; Iwasa S; Okita NT; Honma Y; Takashima A; Kato K; Hamaguchi T; Shimada Y; Nakagawa K; Nishio K; Yamada Y
Oncotarget; 2014 May; 5(9):2588-95. PubMed ID: 24809949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
